Was RO4929097 Actually Worth The Dough?

7%) and inadequate pain control (47.1%) were the most common side effects. The most common side effect resulting in a hydromorphone-to-morphine switch was nausea (66.7%). However, when pain scores were available, the current data demonstrate no difference in the pain scores during the initial 24 hours of NCA when comparing fentanyl, morphine, and hydromorphone. The major advantage of the current study is that it used institutionally defined criteria for severe adverse events, as indicated by the activation of the Code Blue and RRT. One limitation of this approach is that we may have missed complications of NCA not severe enough to lead to activation of these teams. Another potential limitation of the database used may be inconsistent attribution of adverse events to complications of NCA. However, this was supplemented by noting when a change Nutlin 3 in the opioid prescription was required. For example, five RRT events occurred in patients where the NCA agent was changed (four of five of these events resulted in a switch from morphine to another opioid). However, in review, none of the RRTs were primarily attributed to NCA-related causes. The limitations of our data precluded more detailed investigation of the safety and side effects of changes in NCA agents. While non-life-threatening RO4929097 in vivo adverse effects may be lost in retrospective reviews of the hospital records, bothersome adverse effects or inadequate analgesia would be identified accurately INPP5D as a medication change. Conclusion Authorized Agent-Controlled Analgesia (AACA) offers many advantages to pain management in children. At our institution, NCA is the standard form of AACA used in patients